Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002,an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET Alterations
PFL-002/VERT-002 isa monoclonal antibody with a novel and differentiated mechanism of action,acting as a degrader of c-MET,with the potential to be a best-in-class treatment for cancer driven by MET alterations
CASTRES,France,Oct. 24,2024 -- PierreFabre Laboratories announced today that the first patient has been dosed with PFL-002/VERT-002,a monoclonal antibody acting as a degrader of c-MET,in a phase I/II first-in-human dose-escalation,dose-optimization and dose-expansion trial,for patients with Non-Small Cell Lung Cancer (NSCLC) harbouring MET alterations.
The PFL-002/VERT-002 phase I/II trial is an open label,multi-centre study that aims to assess the safety,tolerability,pharmacokinetics,pharmacodynamics and preliminary clinical efficacy of PFL-002/VERT-002,as a monotherapy for patients with MET-dependent tumors,including those emerging with acquired resistance to other treatments.
Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer,accounting for approximately 85% of newly diagnosed lung cancer cases,and MET,also known as hepatocyte growth factor receptor (HGFR),is an oncogene driver in subsets of patients suffering from NSCLC.1-4MET exon 14 skipping mutation and MET amplification are found as primary oncogenic drivers and MET amplification as a resistance mechanism to selected targeted therapies.
"PFL-002/VERT-002 targets a clinically validated oncogenic driver with a unique and differentiated mechanism of action,triggering the degradation of the c-MET oncogene. Thus,it provides the opportunity to test a novel therapeutic approach for patients with MET driven tumors. We are looking forward to collaborating with the investigators participating in the first-in-human trial to assess the safety and efficacy of this new agent."saidFrancesco Hofmann,Head of Research and Development for Medical Care at Pierre Fabre Laboratories.
Contact: laure.sgandurra@pierre-fabre.com
PDF - https://mma.prnewswire.com/media/2538658/Pierre_Fabre_PFL_002_Vert_002.pdf
